Patents by Inventor Boris Kroeplien

Boris Kroeplien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9932334
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: April 3, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Patent number: 9926313
    Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: March 27, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Fabien Claude Lecomte, John Robert Porter
  • Patent number: 9902720
    Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 27, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Daniel Christopher Brookings, Victoria Elizabeth Jackson, Boris Kroeplien
  • Patent number: 9890154
    Abstract: A series of substituted 3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 13, 2018
    Assignee: UCB Biopharma SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Patent number: 9890174
    Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: February 13, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu
  • Patent number: 9873703
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 23, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter, Joanna Rachel Quincey
  • Patent number: 9868749
    Abstract: A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: January 16, 2018
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Rikki Peter Alexander, Jonathan Mark Bentley, Gareth Neil Brace, Daniel Christopher Brookings, Prafulkumar Tulshibhai Chovatia, Hervé Jean Claude Deboves, Craig Johnstone, Elizabeth Pearl Jones, Boris Kroeplien, Fabien Claude Lecomte, James Madden, Craig Miller, John Robert Porter, Matthew Duncan Selby, Michael Alan Shaw, Darshan Gunvant Vaidya, Ian Andrew Yule
  • Patent number: 9834553
    Abstract: A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: December 5, 2017
    Assignee: UCB BIOPHARMA SPRL
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Patent number: 9815797
    Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: December 8, 2014
    Date of Patent: November 14, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Rikki Peter Alexander, Gregory Foulkes, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, James Thomas Reuberson, Sarah Margaret Rook, Zhaoning Zhu
  • Publication number: 20170129883
    Abstract: A series of substituted 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine derivatives, being potent treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 11, 2017
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, Martin Alexander Lowe, John Robert Porter
  • Publication number: 20170128445
    Abstract: A series of substituted benzimidazole, imidazo[1,2-?]pyridine and pyrazolo[1,5-?]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: May 11, 2017
    Inventors: Julien Alistair Brown, Mark Daniel Calmiano, Elizabeth Pearl Jones, Boris Kroeplien, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu
  • Publication number: 20170081321
    Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: March 23, 2017
    Inventors: Daniel Christopher Brookings, Victoria Elizabeth Jackson, Boris Kroeplien
  • Patent number: 9550737
    Abstract: A series of benzimidazole derivatives, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: January 24, 2017
    Assignee: UCB Biopharma SPRL
    Inventors: Daniel Christopher Brookings, Mark Daniel Calmiano, Ellen Olivia Gallimore, Helen Tracey Horsley, Martin Clive Hutchings, James Andrew Johnson, Boris Kroeplien, Fabien Claude Lecomte, Martin Alexander Lowe, Timothy John Norman, John Robert Porter, Joanna Rachel Quincey, James Thomas Reuberson, Matthew Duncan Selby, Michael Alan Shaw, Zhaoning Zhu, Anne Marie Foley
  • Publication number: 20160376268
    Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Rikki Peter ALEXANDER, Gareth Neil BRACE, Julien Alistair BROWN, Mark Daniel CALMIANO, Praful Tulshi CHOVATIA, Michael DELIGNY, Ellen Olivia GALLIMORE, Jag Paul HEER, Victoria Elizabeth JACKSON, Boris KROEPLIEN, Malcolm MAC COSS, Joanna Rachel QUINCEY, Yogesh Anil SABNIS, Dominique Louis Léon SWINNEN, Zhaoning ZHU, Uwe HEINELT, Volkmar WEHNER
  • Publication number: 20160376275
    Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 29, 2016
    Inventors: Mezher Hussein ALI, Daniel Christopher BROOKINGS, Julien Alistair BROWN, Martin Clive HUTCHINGS, Victoria Elizabeth JACKSON, Boris KROEPLIEN, John Robert PORTER, Joanna Rachel QUINCEY
  • Publication number: 20160355509
    Abstract: A series of substituted 3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: December 8, 2016
    Inventors: Victoria Elizabeth Jackson, Boris Kroeplien, John Robert Porter
  • Publication number: 20160304470
    Abstract: A series of substituted heteroaromatic compounds containing two fused six-membered rings, tivity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Gregory Foulkes, Martin Clive Hutchings, Victoria Elizabeth Jackson, Boris Kroeplien, James Thomas Reuberson, Sarah Margaret Rook, Zhaoning Zhu
  • Publication number: 20160304513
    Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Michael Louis Robert Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Boris Kroeplien, Fabien Claude Lecomte, John Robert Porter
  • Publication number: 20160304523
    Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Mark Daniel Calmiano, Sabine Defays, Veronique Durieu, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Jean Keyaerts, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Matthew Duncan Selby, Dominique Louis Leon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu, Uwe Heinelt, Volkmar Wehner
  • Publication number: 20160304530
    Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4?,3?:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c?]dipyridine, dihydro-1H-pyrano[3?,4?:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogues thereof, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: December 8, 2014
    Publication date: October 20, 2016
    Inventors: Rikki Peter Alexander, Julien Alistair Brown, Michael Deligny, Jag Paul Heer, Victoria Elizabeth Jackson, Sophie Jadot, Boris Kroeplien, Malcolm Mac Coss, Yogesh Anil Sabnis, Dominique Louis Léon Swinnen, Nathalie Van Houtvin, Zhaoning Zhu